UK Markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.56-0.49 (-3.49%)
At close: 04:00PM EST
13.56 0.00 (0.00%)
After hours: 06:03PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.58
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 323.64
52-week low 311.75
50-day moving average 316.89
200-day moving average 315.59

Share statistics

Avg vol (3-month) 399.86k
Avg vol (10-day) 3116.46k
Shares outstanding 529.67M
Implied shares outstanding 6N/A
Float 821.46M
% held by insiders 116.42%
% held by institutions 158.16%
Shares short (12 Aug 2021) 42.64M
Short ratio (12 Aug 2021) 429.07
Short % of float (12 Aug 2021) 410.30%
Short % of shares outstanding (12 Aug 2021) 48.20%
Shares short (prior month 14 Jul 2021) 42.64M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)-412.87%

Management effectiveness

Return on assets (ttm)-43.61%
Return on equity (ttm)-92.11%

Income statement

Revenue (ttm)18.35M
Revenue per share (ttm)0.68
Quarterly revenue growth (yoy)198.10%
Gross profit (ttm)-57.67M
EBITDA -75.07M
Net income avi to common (ttm)-75.52M
Diluted EPS (ttm)-3.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)99.22M
Total cash per share (mrq)3.09
Total debt (mrq)7.44M
Total debt/equity (mrq)8.24
Current ratio (mrq)8.29
Book value per share (mrq)4.01

Cash flow statement

Operating cash flow (ttm)-69.69M
Levered free cash flow (ttm)-39.42M